Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment

**Overview**

This COCA Call will present the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers will discuss what is known about CVST, the importance of early detection, and updated vaccine recommendations.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

The slide set will be available under "Call Materials" on the COCA Call webpage the day of the call.

Continuing Education (CE) will not be provided for this call.

**Date:** Thursday, April 15, 2021

**Time:** 2:00 pm - 3:00 pm (ET)

A few minutes before the webinar starts, please click on the Zoom link below to join:

https://www.zoomgov.com/j/1614336614?pwd=ZVhQUHoyaG4zVFdu2czcE9EU20wUT09

Or iPhone one-tap:

US: +16692545252,,1614336614#,,,,*160026#
Advanced registration is not required.

Or
+16468287666,,1614336614#,,,160026#

Or Telephone: Dial (for higher quality, dial a number based on your current location):
US +1 669 254 5252 or
+1 646 828 7666 or
+1 551 285 1373 or
+1 669 216 1590

Webinar ID: 161 433 6614
Passcode: 160026

International numbers available:
hits://www.zoomgov.com/u/acVEZz9i4e

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC’s role in the topic covered during the presentation.
3. Describe the topic’s implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Presenters

Sara Oliver, MD
LCDR, U.S. Public Health Service
Co-lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group
COVID-19 Response
Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA
CAPT, U.S. Public Health Service
Vaccine Safety Team Lead
COVID-19 Response
The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov

- CDC Clinician Outreach and Communication Activity Facebook page—connect with COCA on Facebook
- Clinician Outreach and Communication Activity—resources for healthcare providers
- COCA RSS Feed—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
- Crisis & Emergency Risk Communication Training—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
- Health Alert Network—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories

CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.